Hepatocellular carcinoma
Conditions
Interventions
Control group (High risk group of HCC, average risk group of HCC, interference control):None
HCC screening population (Liver cirrhosis due to various causes, chronic hepatitis B or C with an age =40 years):None
Disease group (Hepatocellular carcinoma):None
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.HCC group: ?Male or female, age =18 years old; ?Pathologically and/or clinically diagnosed as hepatocellular carcinoma; ?Voluntarily participate in this study and ability to provide a written informed consent.; 2.High risk group of HCC: ?Male or female, age =18 years old; ?No prior diagnosis of HCC, and no clinically and/or radiographically diagnosed suspicious malignancy; ?Meeting any of the following criteria: chronic hepatitis B, chronic hepatitis C, liver cirrhosis, alcoholic liver disease, non-alcoholic steatohepatitis, family history of liver cancer, long-term consumption of foods contaminated with aflatoxins; ?Voluntarily participate in this study and ability to provide a written informed consent.; 3.Average risk group of HCC: ?Male or female, age =18 years old; ?No prior diagnosis of HCC, and no clinically and/or radiographically diagnosed suspicious malignancy; ?No risk factors for HCC mentioned above; ?Voluntarily participate in this study and ability to provide a written informed consent.; 4.Interference control group: ?Male or female, age =18 years old; ?No prior diagnosis of HCC, and no clinically and/or radiographically diagnosed suspicious malignancy; ? Pathological diagnosis of any of the following malignant tumors: gallbladder cancer, cholangiocarcinoma, pancreatic cancer, gastric cancer, and colorectal cancer; ?Voluntarily participate in this study and ability to provide a written informed consent.; 5.HCC screening population: ?Male or female, age =18 years old; ?Meeting any of the following criteria: patients with liver cirrhosis due to various causes, chronic hepatitis B or C with an age =40 years; ?Voluntarily participate in this study and ability to provide a written informed consent.;
Exclusion criteria
Exclusion criteria: 1.Known prior or current diagnosis of other types of malignancies or multiple primary tumors (excluding non-melanoma skin cancers); 2.Prior or ongoing anti-cancer therapy (including surgical resection, chemotherapy, radiotherapy, interventional therapy, targeted therapy, immunotherapy, and neoadjuvant therapy) prior to study blood draw; 3.Pregnancy women; 4.Any uncontrolled co-existing medical condition that may limit compliance with study requirements or affect written informed consent procedure, including but not limited to: persistent or active infection, symptomatic congestive heart failure, unstable angina, arrhythmia, myocardial infarction, severe seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or mental illness; 5.Recipients of organ transplant or prior bone marrow transplant or stem cell transplant; 6.Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer, including methylpterin, cyclophosphamide, azathioprine, and phenylbutyrate nitrogen mustard, etc. 7.Recipients of blood transfusion (including component blood) within 2 weeks prior to study blood draw; 8.Poor general condition or inability to tolerate blood drawing and related tests; 9.Subjects deemed unsuitable for inclusion in the study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactGao Jie
Peking University People's Hospital
Outcome results
None listed